SHP-2 and myeloid malignancies

Current Opinion in Hematology

Volumn 11, Issue 1, 2004, Pages 44-50

  Tartaglia, Marco ^a   Niemeyer, Charlotte M ^b   Shannon, Kevin M ^c   Loh, Mignon L ^c  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gain of function; JMML; Leukemogenesis; Noonan syndrome; PTPN11; RAS signaling

Indexed keywords

GENE PRODUCT; GUANOSINE TRIPHOSPHATE; NEUROFIBROMIN; PROTEIN PTPN11; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; CANCER SUSCEPTIBILITY; ENZYME ACTIVITY; ENZYME STRUCTURE; GENE FUNCTION; GENE MUTATION; GENETIC CODE; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMOGENESIS; MYELOID LEUKEMIA; NOONAN SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; UPREGULATION;

HEMATOPOIESIS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID; MUTATION; NOONAN SYNDROME; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE-PHOSPHATASE; SIGNAL TRANSDUCTION;

EID: 0347510589     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200401000-00007     Document Type: Review

References (71)

1. Stein-Gerlach M, Wallasch C, Ullrich A: SHP-2, SH2-containing protein tyrosine phosphatase-2. Int J Biochem Cell Biol 1998, 30:559-566.
2. Feng G-S: Shp-2 tyrosine phosphatase: signaling one cell or many. Exp Cell Res 1999, 253:47-54.
3. Huyer G, Alexander DR: Immune signalling: SHP-2 docks at multiple ports. Curr Biol 1999, 9:R1 29-R132.
4. Qu C-K: Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response. Biochim Biophys Acta 2002, 1592:297-301.
5. Neel BG, Gu H, Pao L: The'Shp'ing news: SH2 domain-containing tyrosine phosphatase in cell signaling. Trends Biochem Sci 2003, 28:284-293.
6. Adachi M, Sekiya M, Miyachi T, et al.: Molecular cloning of a novel protein-tyrosine phosphatase SH-PTP3 with sequence similarity to the src-homology region 2. FEBS Lett 1992, 314:335-339.
7. Freeman RM Jr, Plutzky J, Neel BG: Identification of a human src homology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew. Proc Natl Acad Sci U S A 1992, 89:11239-11243.
8. Ahmad S, Banville D, Zhao Z, et al.: A widely expressed human protein-tyrosine phosphatase containing src homology 2 domains. Proc Natl Acad Sci U S A 1993, 90:2197-2201.
9. Feng G-S, Hui C-C, Pawson T: SH-2 containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases, Science 1993, 259:1607-1611.
10. Pluskey S, Wandless TJ, Walsh CT, Shoelson SE: Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains. J Biol Chem 1995, 270:2897-2900.
11. Hof P, Pluskey S, Dhe-Paganon S, et al.: Crystal structure of the tyrosine phosphatase SHP-2. Cell 1998, 92:441-450. This study reports the crystal structure of SHP-2 in its autoinhibited, closed conformation and illustrates the conformational switch mechanism controlling SHP-2 catalytic activation and subcellular relocalization.
12. Saxton TM, Henkemeyer M, Gasca S, et al.: Abnormal mesoderm pattering in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J 1997, 16:2352-2364.
13. Maroun CR, Naujokas MA, Holgado-Madruga M, et al.: The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol 2000, 20:8513-8525.
14. Shi Z-Q, Yu D-H, Park M, et al.: Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity. Mol Cell Biol 2000, 20:1526-1536.
15. Cunnick JM, Meng S, Ren Y, et al.: Regulation of the mitogen-activated protein kinase signaling pathway by SHP-2. J Biol Chem 2002, 277:9498-9504.
16. You M, Flock LM, Yu D, Feng G-S: Modulation of the nuclear factor κB pathway by Shp-2 tyrosine phosphatase in mediating the induction of interleukin (IL)-6 by IL-1 or tumor necrosis factor. J Exp Med 2001, 193:101-109.
17. You M, Yu D-H, Feng G-S: Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol 1999, 19:2416-2424.
18. Chen Y, Wen R, Yang S, et al.: Identification of Shp-2 as a Stat5A phosphatase. J Biol Chem 2003, 278:16520-16527.
19. Wu CJ, O'Rourke DM, Feng GS, et al.: The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors. Oncogene 2001, 20:6018-6025.
20. Zhang SQ, Tsiaras WG, Araki T, et al.: Receptor-specific regulation of phosphatidylinositol 3′-kinase activation by the protein tyrosine phosphatase Shp2. Mol Cell Biol 2002, 22:4062-4072.
21. Ekman S, Kallin A, Engstrom U, et al.: SHP-2 is involved in heterodimer specific loss of phosphorylation of Tyr771 in the PDGF beta-receptor. Oncogene 2002, 21:1870-1875.
22. Bennett AM, Tang TL, Sugimoto S, et al.: Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc Natl Acad Sci U S A 1994, 91:7335-7339.
23. Li W, Nishimura R, Kashishian A, et al.: A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase. Mol Cell Biol 1994, 14:509-517.
24. Tauchi T, Feng GS, Marshall MS, et al.: The ubiquitously expressed Syp phosphatase interacts with c-kit and Grb2 in hematopoietic cells. J Biol Chem 1994, 269:25206-25211.
25. Tauchi T, Damen JE, Toyama K, et al.: Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation, and promotes mitogenesis. Blood 1996, 87:4495-4501.
26. Itoh T, Liu R, Yokota T, et al.: Definition of the role of tyrosine residues of the common beta subunit regulating multiple signaling pathways of granulocyte-macrophage colony-stimulating factor receptor. Mol Cell Biol 1998, 18:742-752.
27. Maeda A, Kurosaki M, Ono M, et al.: Requirement of SH2-containing protein tyrosine phosphatases SHP-1 and SHP-2 for paired immunoglobulin-like receptor B (PIR-B)-mediated inhibitory signal. J Exp Med 1998, 187:1355-1360.
28. Mustelin T, Brockdorff J, Gjorloff-Wingren A, et al.: Lymphocyte activation: the coming of the protein tyrosine phosphatases. Front Biosci 1998, 3:D1060-D1096.
29. Ward AC, Monkhouse JL, Hamilton JA, Csar XF: Direct binding of Shc, Grb2, SHP-2 and p40 to the murine granulocyte colony-stimulating factor receptor. Biochim Biophys Acta 1998, 1448:70-76.
30. Edmead CE, Crosby DA, Southcott M, Poole AW: Thrombin-induced association of SHP-2 with multiple tyrosine-phosphorylated proteins in human platelets. FEBS Lett 1999, 459:27-32.
31. Gu H, Pratt JC, Burakoff SJ, Neel BG: Cloning of p97/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation. Mol Cell 1998, 2:729-740.
32. Zhao C, Yu DH, Shen R, Feng GS: Gab2, a new pleckstrin homology domain-containing adapter protein, acts to uncouple signaling from ERK kinase to Elk-1. J Biol Chem 1999, 274:19649-19654.
33. Liu Y, Jenkins B, Shin JL, Rohrschneider LR: Scaffolding protein Gab2 mediates differentiation signaling downstream of Fms receptor tyrosine kinase. Mol Cell Biol 2001, 21:3047-3056.
34. Yu WM, Hawley TS, Hawley RG, Qu CK: Role of the docking protein Gab2 in beta(1)-integrin signaling pathway-mediated hematopoietic cell adhesion and migration. Blood 2002, 99:2351-2359.
35. Sattler M, Mohi MG, Pride YB, et al.: Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 2002, 1:479-492.
36. Tang TL, Freeman RM Jr, O'Reilly AM, et al.: The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early Xenopus development. Cell 1995, 80:473-483.
37. Qu C-K, Yu W-M, Azzarelli B, et al.: Biased suppression of hematopoiesis and multiple developmental defects in chimeric mice containing Shp-2 mutant cells. Mol Cell Biol 1998, 18:6075-6082.
38. Saxton TM, Ciruna BG, Holmyard D, et al.: The SH2-tyrosine phosphatase Shp2 is required for mammalian limb development. Nat Genet 2000, 24:420-423.
39. Chen B, Bronson RT, Klaman LD, et al.: Mice mutants for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat Genet 2000, 24:296-299.
40. Qu C-K, Shi Z-Q, Shen R, et al.: A deletion mutation in the SH2-N domain of Shp-2 severely suppress hematopoietic cell development. Mol Cell Biol 1997, 17:5499-5507. By analyzing the in vitro differentiation of embryonic stem cells expressing a Shp-2 null mutant, this group provides evidence that Shp-2 loss-of-function severely suppresses development of erythroid progenitors and completely blocks the production of myeloid progenitor cells.
41. -/- embryonic stem cells into Rag-2-deficient blastocysts do not have detectable mature B and T cells. Moreover, by using a genetic approach, this study also shows that Shp-2 and Shp-1 have antagonistic function in hematopoiesis.
42. Pazdrak K, Adachi T, Alam R: Src homology 2 protein tyrosine phosphatase (SHPTP2)/Scr homology 2 phosphatase 2 (SHP2) tyrosine phosphatase is a positive regulator of the interleukin 5 receptor signal transduction pathways leading to the prolongation of eosinophil survival. J Exp Med 1997, 186:561-568.
43. Bordin L, Brunati AM, Donella-Deana A, et al: Band 3 is an anchor protein and a target for SHP-2 tyrosine phosphatase in human erythrocytes. Blood 2002, 100:276-282.
44. Ohtani T, Ishihara K, Atsumi T, et al.: Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. Immunity 2000, 12:95-105.
45. Newman DK, Hamilton C, Newman PJ: Inhibition of antigen-receptor signaling by platelet endothelial cell adhesion molecule-1 (CD31) requires functional ITIMs, SHP-2, and p56(lck). Blood 2001, 97:2351-2357.
46. Koncz G, Pecht I, Gergely J, Sarmay G: Fcgamma receptor-mediated inhibition of human B cell activation: the role of SHP-2 phosphatase. Eur J Immunol 1999, 29:1980-1989.
47. Sarmay G, Koncz G, Pecht I, Gergely J: Cooperation between SHP-2, phosphatidyl inositol 3-kinase and phosphoinositol 5-phosphatase in the Fc gamma RIIb mediated B cell regulation. Immunol Lett 1999, 68:25-34.
48. Tartaglia M, Gelb BD: Noonan syndrome and PTPN11. In The Molecular Basis of Inborn Errors of Development. Edited by Epstein CJ, Erickson RP, Wynshaw-Boris A. San Francisco, CA: Oxford University Press; 2003, in press.
49. Tartaglia M, Mehler EL, Goldberg R, et al.: Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001, 29:465-468.
50. Digilio MC, Conti E, Sarkozy A, et al.: Grouping of multiple-lentigines/ LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 2002, 71:389-394.
51. Legius E, Schrander-Stumpel C, Schollen E, et al.: PTPN11 mutations in LEOPARD syndrome. J Med Genet 2002, 39:571-574.
52. Tartaglia M, Kalidas K, Shaw A, et al.: PTPN11 Mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 2002, 70:1555-1563.
53. Bader-Meunier B, Tchernia G, Miélot F, et al.: Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr 1997, 130:885-889.
54. Choong K, Freedman MH, Chitayat D, et al.: Juvenile myelomonocytic leukemia and Noonan syndrome. J Pediatr Hematol Oncol 1999, 21:523-527.
55. Emanuel PD, Shannon KM, Castleberry RP: Juvenile myelomonocitic leukemia: molecular understanding and prospects for therapy. Mol Med Today 1996, 2:468-475.
56. Aricò M, Biondi A, Pui C-H: Juvenile myelomonocytic leukemia. Blood 1997, 90:479-488.
57. Emanuel PD, Bates LJ, Castleberry RP, et al.: Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991, 77:925-929.
58. Birnbaum RA, O'Marcaigh A, Wardak Z, et al.: Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell 2000, 5:189-195. By generating Nf1- and Gmcsf-deficient hematopoietic cells, this group shows that GM-CSF plays a central role in establishing and maintaining the JMML-like myeloproliferative disorder observed in Nf1-deficient mice.
59. Iversen PO, Emanuel PD, Sioud M: Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile myelomonocytic leukemia cell growth. Blood 2002, 99:4147-4153.
60. Kalra R, Paderanga DC, Olson K, Shannon KM: Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21 ras. Blood 1994, 84:3435-3439. 41 genetic approach is used to test the hypothesis that neurofibromin negatively regulates myeloid cell growth by modulating RAS function.
61. Miyauchi J, Asada M, Sasaki M, et al.: Mutations of the N-RAS gene in juvenile chronic myelogenous leukemia. Blood 1994, 83:2248-2254.
62. Side LE, Emanuel PD, Taylor B, et al.: Mutations of the NF1 gene in children with juvenile myelomonocitic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 1998, 92:267-272.
63. Flotho C, Valcamonica S, Mach-Pascual S, et al.: RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 1999, 13:32-37.
64. Shannon KM, O'Connell P, Martin GA, et al.: Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994, 330:597-601.
65. Side L, Taylor B, Cayouette M, et al.: Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 1997, 336:1713-1720.
66. Tartaglia M, Niemeyer CM, Fragale A, et al.: Somatic PTPN11 mutations in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003, 34:148-150. First molecular evidence for the oncogenic role of a class of PTPN11 mutations in leukemogenesis. The study identifies PTPN11 as the most frequently mutated gene in JMML. The molecular and clinical data support that mutations in PTPN11, KRAS2, NRAS, and NF1 are mutually exclusive in this condition.
67. Loh ML, Vattikuti S, Schubbert S, et al.: Somatic mutations in PTPN11 implicate the protein tyrosine phosphatase SHP-2 in leukemogenesis [abstract]. Blood 2003, in press.
68. Loh ML, Reynolds MG, Vattikuti S, et al.: Incidence and prognostic significance of PTPN11 mutations in pediatric acute myelogenous leukemia-results from Children's Cancer Group trials 2941 and 2961 [abstract]. Blood 2003, in press.
69. O'Reilly AM, Pluskey S, Shoelson SE, Neel BG: Activated mutants of SHP-2 preferentially induce elongation of Xenopus animal caps. Mol Cell Biol 2000, 20:299-311.
70. Sawyers CL, Denny CT: Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about. Cell 1994, 77:171-173.
71. Tartaglia M, Martinelli S, Cazzaniga G, et al.: PTPN11 is mutated in pediatric acute lymphoblastic leukemia [abstract]. Blood 2003 (in press).